Robert Casson

Prof. Robert Casson


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2012 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
RCRobert Casson
Robert Casson
GCGlyn Chidlow
Glyn Chidlow
JWJohn Pm Wood
John Pm Wood
JCJonathan G Crowston
Jonathan G Crowston
IGIvan Goldberg
Ivan Goldberg

28 July 2020 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Open access
PDF file
FHFlora Hui
Flora Hui
JTJessica Tang
Jessica Tang
PWPete Williams
Pete Williams
MMMyra McGuinness
Myra McGuinness
XHXavier Hadoux
Xavier Hadoux
JCJonathan G. Crowston
Jonathan G. Crowston
Importance: Retinal ganglion cells endure significant metabolic stress in glaucoma but maintain capacity to recover function. Nicotinamide, a precursor of NAD+, is low in serum of glaucoma patients and its supplementation provides robust protection of retinal ganglion cells in preclinical models. However, the potential of nicotinamide in human glaucoma is unknown.Background: To examine the effects of nicotinamide on inner retinal function in glaucoma, in participants receiving concurrent glaucoma therapy.Design: Crossover, double‐masked, randomized clinical trial. Participants recruited from two tertiary care centres.Participants: Fifty‐seven participants, diagnosed and treated for glaucoma.Methods: Participants received oral placebo or nicotinamide and reviewed six‐weekly. Participants commenced 6 weeks of 1.5 g/day then 6 weeks of 3.0 g/day followed by crossover without washout. Visual function measured using electroretinography and perimetry.Main outcome measures: Change in inner retinal function, determined by photopic negative response (PhNR) parameters: saturated PhNR amplitude (Vmax), ratio of PhNR/b‐wave amplitude (Vmax ratio).Results: PhNR Vmax improved beyond 95% coefficient of repeatability in 23% of participants following nicotinamide vs 9% on placebo. Overall, Vmax improved by 14.8% [95% CI: 2.8%, 26.9%], (P = .02) on nicotinamide and 5.2% [−4.2%, 14.6%], (P = .27) on placebo. Vmax ratio improved by 12.6% [5.0%, 20.2%], (P = .002) following nicotinamide, 3.6% [−3.4%, 10.5%], (P = .30) on placebo. A trend for improved visual field mean deviation was observed with 27% improving ≥1 dB on nicotinamide and fewer deteriorating (4%) compared to placebo (P = .02).Conclusions: Nicotinamide supplementation can improve inner retinal function in glaucoma. Further studies underway to elucidate the effects of long‐term nicotinamide supplementation.

27 June 2016 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
DNDaniel S. Narayan
Daniel S. Narayan
JWJohn P. M. Wood
John P. M. Wood
GCGlyn Chidlow
Glyn Chidlow
RCRobert Casson
Robert Casson

1 January 2006 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
RCRobert Casson
Robert Casson

14 December 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JHJeffrey M. Harder
Jeffrey M. Harder
CGChelsea Guymer
Chelsea Guymer
JWJohn P. M. Wood
John P. M. Wood
EDEvangelia Daskalaki
Evangelia Daskalaki
GCGlyn Chidlow
Glyn Chidlow
SJSimon W. M. John
Simon W. M. John
Significance: Age-related bioenergetic insufficiency increases the vulnerability of retinal ganglion cells to intraocular pressure during glaucoma pathogenesis. This paper addresses these relationships and provides a deeper understanding of this common neurodegeneration. We demonstrate an intraocular pressure-dependent decline in retinal pyruvate levels coupled to dysregulated glucose metabolism, and detected mTOR activation at the mechanistic nexus of neurodegeneration and metabolism. Supporting this, oral supplementation of pyruvate or mTOR inhibition by rapamycin strongly protects from neurodegeneration. Bioenergetic enhancement thus provides a readily clinically translatable strategy for neurodegenerative disease. This study provides important avenues for neuroprotection against glaucoma by targeting key metabolic pathways that may be mirrored in other neurodegenerative diseases in which metabolic dysregulation may play a key role.

1 March 2021 in Progress in Retinal and Eye Research
Verified
Journal Article
Closed access
RCRobert Casson
Robert Casson
GCGlyn Chidlow
Glyn Chidlow
JCJonathan G. Crowston
Jonathan G. Crowston
PWPete A. Williams
Pete A. Williams
JWJohn P.M. Wood
John P.M. Wood